FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial...
Arthur Klausner to speak at FundingPost's early-stage VC breakfast in New York City on May 18
News | 05. 18. 2006
